公司股票增发计划 - AAR CORP宣布开始进行承销注册公开发行，计划发行3,000,000股普通股 [1] - 公司授予承销商30天期权，可额外购买最多450,000股普通股，价格为公开发行价减去承销折扣和佣金 [1] - 此次发行净收益计划用于偿还无担保循环信贷设施下的未偿还借款，以及用于一般公司用途，可能包括为未来收购提供资金 [2] 发行承销与法律细节 - 此次发行的联合账簿管理人为Goldman Sachs & Co LLC、Jefferies和RBC Capital Markets, LLC [2] - 发行依据公司于2023年7月19日向美国证券交易委员会提交的Form S-3架式注册声明进行，该声明已自动生效 [2] - 发行仅通过初步招股说明书补充文件和随附的基本招股说明书进行 [2] 公司背景信息 - AAR CORP是一家全球航空航天和国防售后市场解决方案公司，业务遍及超过20个国家，总部位于芝加哥地区 [4] - 公司通过四个运营部门支持商业和政府客户：部件供应、维修与工程、集成解决方案和远征服务 [4]

SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of ...

TAMPA, FL / ACCESS Newswire / September 25, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the pricing of a public offering of 7,142,862 shares of common stock, together with warrants to purchase up to 7,142,862 shares of common stock at a combined public offering price of $0.70 per share and associated warrant. The warrants will have an exercise price of $0.70 per share, wi ...

Not for distribution to U.S. news wire services or dissemination in the United States. VANCOUVER, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Outcrop Silver & Gold Corporation (TSXV:OCG, OTCQX:OCGSF, DE:MRG) (“Outcrop Silver” or the “Company”) is pleased to announce that it has entered into an agreement with BMO Capital Markets, as sole bookrunner, and Research Capital Corporation, as co-lead agent, on behalf of a syndicate of agents (collectively, the “Agents”), in connection with a best efforts, ...

REDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, announced today the pricing of its underwritten public offering of (i) an aggregate of 11,670,707 shares of its common stock and accompanying commo ...

公开增发核心条款 - 公司宣布完成公开增发定价，向现有及新晋医疗健康机构投资者发行27,000,000股普通股（或其等价物），并附带E系列认股权证（可认购最多27,000,000股普通股）和F系列认股权证（可认购最多27,000,000股普通股）[1] - 每股普通股及附带认股权证的合并发行价格为0.335美元，在扣除配售代理费及其他发行费用前，预计募集资金总额约为900万美元[1] - E系列认股权证和F系列认股权证的行权价格均为每股0.335美元，均立即可行权，E系列认股权证有效期为发行日起五年，F系列认股权证有效期为发行日起12个月[2] 资金用途与发行安排 - 本次发行预计于2025年9月22日左右完成，具体取决于惯例交割条件的满足情况[3] - 公司计划将本次发行的净收益用于资助研发活动、以及作为营运资金和其他一般公司用途[3] - A.G.P./Alliance Global Partners担任此次发行的唯一配售代理[3] 公司业务与管线 - 公司是一家处于后期研发阶段的生物制药公司，致力于发现、开发和商业化针对中枢神经系统、炎症和心脏代谢疾病领域的下一代疗法[6] - 公司当前研发管线包括两个内部发现的新化学实体药物候选物：brilaroxazine (RP5063) 和 RP1208[6] - brilaroxazine 和 RP1208 的成分专利已在美国、欧洲及多个其他国家获得授予[6]

NEW YORK--(BUSINESS WIRE)--Rithm Capital Corp. (NYSE: RITM; "Rithm†or the "Company†) announces that it has launched an opportunistic underwritten public offering of Series E Fixed-Rate Cumulative Redeemable Preferred Stock (the "Preferred Stock†), subject to market conditions. The terms of the Preferred Stock are to be determined by negotiations between the Company and the underwriters. The Company intends to apply to list the Preferred Stock on the New York Stock Exchange under the symbol "RI. ...

SAN JUAN, Puerto Rico, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or “Company”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, announced today the pricing of an underwritten public offering of 15,625,000 shares of common stock at a price to the public of $9.60 per share. The gross proceeds from the offering to the Company are expected to be approximately $150 million, before deducting underwr ...

公司融资活动 - AIRO集团控股公司完成增发483万股普通股 包括承销商全额行使630,000股超额配售权[1] - 本次公开发行获得总收益未披露具体金额 扣除费用前数据未完整呈现[1] - 股票发行于2025年9月12日完成 发行规模较原计划有所扩大[1] 公司业务领域 - 公司专注于先进航空航天与国防技术领域 在纳斯达克交易所上市交易代码为AIRO[1] - 业务覆盖美国新墨西哥州阿尔伯克基 加拿大蒙特利尔 丹麦斯图林等多个地区[1]

公司融资活动 - Nebius Group NV作为领先AI基础设施公司宣布定价承销公开发行10亿美元A类普通股 每股发行价格92.50美元[1] - 公司授予承销商30天超额配售权 可额外购买最多1.5亿美元A类普通股[1]